文献速递系统性红斑狼疮

美国医疗补助计划中系统性红斑狼疮患者与非患者的骨折风险比较

Comparative Fracture Risks Among United States Medicaid Enrollees With and Those Without Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2019-06-05

本研究基于2007-2010年美国Medicaid索赔数据,纳入47,709例系统性红斑狼疮(SLE)患者(19.8%合并狼疮肾炎)及190,836例年龄性别匹配的非SLE对照,评估骨折风险。结果显示SLE患者骨折风险是非SLE对照的2倍(HR 2.09),狼疮肾炎患者风险最高(HR 3.06),且较无肾炎SLE患者高1.58倍;调整糖皮质激素和合并症后风险仍持续升高。

要点

  • SLE患者骨折风险显著高于匹配非SLE人群(HR 2.09,95%CI 1.85-2.37)。
  • 狼疮肾炎患者骨折风险最高,较对照高3.06倍,较无肾炎SLE高1.58倍。
  • 调整基线糖皮质激素使用和合并症后,骨折风险仍持续升高。

核心结论

  • SLE患者骨折风险较匹配的非SLE医疗补助受助者增加约2倍,狼疮肾炎患者风险最高,调整糖皮质激素和合并症后风险仍持续存在。

研究设计与样本

  • 基于2007-2010年Medicaid索赔数据的队列研究,纳入47,709例SLE患者(19.8%合并狼疮肾炎)及190,836例年龄性别匹配的非SLE对照,平均年龄41.4岁,92.6%为女性。

主要发现

  • SLE患者骨折风险是非SLE对照的2倍(HR 2.09,95%CI 1.85-2.37;P<0.01)。
  • 狼疮肾炎患者骨折风险较匹配对照高3.06倍(HR 3.06,95%CI 2.24-4.17;P<0.01),较无肾炎SLE患者高1.58倍(HR 1.58,95%CI 1.20-2.07;P<0.01)。
  • 狼疮肾炎患者骨折发病率最高(4.60/1000人年)。
  • 调整糖皮质激素使用和合并症后风险略有减弱但仍持续。

关键数值与推荐

  • SLE定义:≥3个国际疾病分类第九版(ICD-9)SLE编码;狼疮肾炎定义:SLE编码基础上≥2个肾脏疾病编码。
  • 主要结局:骨盆、腕、髋或肱骨骨折。

临床怎么用

  • 对SLE患者,尤其合并狼疮肾炎者,应重视骨折风险评估与骨健康管理。
  • 即使调整糖皮质激素和合并症后骨折风险仍高,提示需关注SLE疾病本身及肾脏受累对骨健康的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Poor bone health is common in systemic lupus erythematosus (SLE) patients. This study was undertaken to evaluate fracture risks among low-income SLE and lupus nephritis patients compared to those without SLE. METHODS: We performed a cohort study among SLE patients for whom there were Medicaid claims in 2007-2010, and age- and sex-matched non-SLE comparators. SLE was defined by the presence of ≥3 International Classification of Diseases, Ninth Revision codes for SLE. Patients with lupus nephritis additionally had ≥2 codes for renal disease. The primary outcome measure was fracture of the pelvis, wrist, hip, or humerus. Demographics, prescriptions, and comorbidities were assessed during the 180-day baseline period. We calculated fracture incidence rates and 95% confidence intervals (95% CIs) in SLE, lupus nephritis, and non-SLE comparator cohorts, and estimated adjusted hazard ratios (HRs) for fractures. Sensitivity analyses evaluated the impact of glucocorticoids and comorbidities. We compared subsets of SLE patients with and those without lupus nephritis. RESULTS: Among 47,709 SLE patients (19.8% with lupus nephritis) matched to 190,836 non-SLE comparators, the mean age was 41.4 years and 92.6% were female. The fracture incidence rate was highest among SLE patients with lupus nephritis (4.60 per 1,000 person-years). SLE patients had 2-fold higher fracture risks than matched comparators (HR 2.09 [95% CI 1.85-2.37]; P < 0.01). Lupus nephritis patients had the greatest fracture risks versus matched comparators (HR 3.06 [95% CI 2.24-4.17]; P < 0.01), and had a 1.6 times higher fracture risk than SLE patients without nephritis (HR 1.58 [95% CI 1.20-2.07]; P < 0.01). Adjustment for glucocorticoid use and comorbidities slightly attenuated risks. CONCLUSION: Fracture risks were increased in SLE patients, particularly those with lupus nephritis, compared to matched non-SLE Medicaid recipients. Increased risks persisted after adjustment for baseline glucocorticoid treatment and comorbidities.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tedeschi SK, Kim SC, Guan H, et al. Comparative Fracture Risks Among United States Medicaid Enrollees With and Those Without Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019. PMID: 30714690. doi:10.1002/art.40818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。